This phase II trial studies the effects and safety of adding ablative local therapy (ALT) to the usual systemic therapy in treating patients with solid tumors that have spread from where it first started (primary site) to other places in the body (metastatic) and has progressed to up to 5 body sites (oligo-progressive). Stereotactic body radiation therapy (SAbR) is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body (except the brain). The total dose of radiation is divided into smaller doses given over several days. This type of radiation therapy helps spare normal tissue. Radiofrequency ablation uses a needle to deliver a high-frequency, electric current to kill tumor cells by heating them. IR ablation therapy, such as microwave ablation kills tumor cells by heating them to several degrees above normal body temperature. The addition of ablative local therapy to the usual approach of systemic therapy could be more effective than usual chemotherapy alone by increasing the life of patients with oligo-progressive solid tumors.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT06103669.
Locations matching your search criteria
United States
California
Chico
Enloe Medical CenterStatus: Active
Contact: Jonathan Edgar Clark
Phone: 530-332-7300
Marysville
Fremont - Rideout Cancer CenterStatus: Active
Contact: Ky Nam Bao Nguyen
Phone: 530-749-4400
Sacramento
University of California Davis Comprehensive Cancer CenterStatus: Active
Contact: Xiao Zhao
Phone: 916-734-5810
Truckee
Gene Upshaw Memorial Tahoe Forest Cancer CenterStatus: Active
Contact: Thomas John Semrad
Phone: 530-582-6450
PRIMARY OBJECTIVE:
I. To evaluate the efficacy of adding locally ablative therapies to systemic treatment regimens in patients with oligo-progressive solid tumors.
SECONDARY OBJECTIVES:
I. To evaluate the toxicities attributable to adding locally ablative therapies to systemic treatment regimens in patients with oligo-progressive solid tumors.
II. To further evaluate the efficacy of adding locally ablative therapies to systemic treatment regimens in patients with oligo-progressive solid tumors.
EXPLORATORY OBJECTIVE:
I. To further evaluate the efficacy of adding locally ablative therapies to systemic treatment regimens in patients with oligo-progressive solid tumors.
OUTLINE:
Patients undergo ablative local therapy with SABR or IR ablation therapy per the discretion of treating radiation oncologist and/or interventional radiologist. Patients also undergo computed tomography (CT) or radiologic imaging throughout the study.
After completion of study treatment, patients are followed up at 3, 6, 9, 12, 18 months, and 2 years.
Lead OrganizationUniversity of California Davis Comprehensive Cancer Center
Principal InvestigatorXiao Zhao
